ZAS Corporation is proud to collaborate with the Rheumatology Department of BIRDEM General Hospital to introduce three world-class biosimilar therapies from Celltrion Healthcare, Korea—Yuflyma® (adalimumab), Truxima® (rituximab), and Remsima® (infliximab).
The initiative was formally marked at a recent CME event, where Dr. Sabrina Yesmin, Associate Professor & Head of the Rheumatology Department, shared her expert insights on the role of biosimilars in enhancing treatment accessibility and improving patient outcomes.
This milestone represents a significant step forward in making advanced, evidence-based rheumatology care more affordable and accessible in Bangladesh, aligning global innovation with local healthcare needs.